Amgen's bone drug as good as Zometa in patients with solid tumours
04 August 2009
Asher Mullard
Please Login to read the full article.
04 August 2009
Asher Mullard
asher.mullard@informa.com
Amgen's denosumab is as effective as Novartis's Zometa for the treatment of bone metastases in patients with solid tumours, show preliminary results of a Phase III trial.
Amgen has high hopes for denosumab, a potential blockbuster drug that recently outperformed Zometa in a head-to-head...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen & UCB unveil positive AMG 785/CDP7851 PMO data
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
- FDA panel calls for clarity on duration of bone drug use, but sets no cutoff
- In bone drug quandary, FDA seeks panel's advice on safety, 'drug holidays'
ANALYSIS
Other Informa Analysis
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
